Related Experiment Videos
Short peptide-based tolerogens without self-antigenic or pathogenic activity reverse autoimmune disease
1Department of Neurology and Neurological Sciences, Beckman Center for Molecular and Genetic Medicine-B002, Stanford University School of Medicine, CA 94305, USA.
Journal of Immunology (Baltimore, Md. : 1950)
|May 20, 1998
Summary
Shortened myelin basic protein peptides effectively treat autoimmune diseases like multiple sclerosis by acting as tolerogens. These non-antigenic peptides reverse paralysis and anergize autoreactive T cells, offering therapeutic potential.
Area of Science:
- Neuroimmunology
- Autoimmune disease research
- Peptide therapeutics
Background:
- Myelin basic protein (MBP) p87-99 is an immunodominant epitope targeted by T cells in multiple sclerosis (MS) lesions.
- This MBP peptide can induce experimental autoimmune encephalomyelitis (EAE), a model for MS.
Purpose of the Study:
- To design non-antigenic truncated peptides based on the pathogenic MBP p87-99 epitope.
- To evaluate the therapeutic potential of these truncated peptides in autoimmune disease models.
Main Methods:
- Design and synthesis of truncated peptides derived from MBP p87-99.
- In vivo assessment of peptide antigenicity and immunomodulatory effects (IFN-gamma, TNF-alpha production).
- Evaluation of therapeutic efficacy in a rat model of EAE (paralysis reversal).
Main Results:
- Truncated peptides were non-antigenic but reduced pro-inflammatory cytokine production (IFN-gamma, TNF-alpha).
- A 7-mer truncated peptide (FKNIVTP) completely reversed paralysis in EAE rats within 24 hours.
- These peptides function as effective tolerogens, anergizing autoreactive T cells.
Conclusions:
- Short, non-antigenic peptide tolerogens derived from MBP can effectively treat autoimmune conditions.
- These peptide-based tolerogens demonstrate significant therapeutic potential for autoimmune diseases like MS.
- The strategy offers a promising approach for developing safe and effective autoimmune disease therapies.